Rush Street Interactive invests in, enters partnership with Boom Entertainment 09:04 RSI Rush Street Interactive announced that it has made a minority investment in Boom Entertainment, a game developer and technology provider that has created and operated sports gaming apps in the United States on behalf of numerous brands. In addition to the investment, RSI and Boom have entered into a commercial agreement. As part of that agreement, Boom will integrate its remote gaming server and license online casino and sports betting games for RSI to make available to its real money and social casino players via RSI's proprietary online gaming platform. Boom will also develop certain custom games for which RSI will have exclusivity rights on for at least one year, ensuring RSI will be able to offer its players unique and differentiated games to play. Additionally, through Boom's relationship with certain land-based casinos in Louisiana, Mississippi, and New Mexico, RSI will receive market access opportunities to operate online casino and sports betting in those new states, subject to license availability, state law and regulatory approvals. In Louisiana, RSI expects to launch mobile sports betting operations during the upcoming football season following the legalization of sports betting in the state in June.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
FuboTV price target raised to $40 from $30 at Evercore ISI 09:03 FUBO Evercore ISI analyst Shweta Khajuria raised the firm's price target on FuboTV to $40 from $30 and keeps an Outperform rating on the shares. FuboTV printed a "clean" beat and raise Q2, with revenue, subscribers and ARPU all well above the Street, Khajuria tells investors in a research note. The analyst continues to view Fubo as a key beneficiary to cord cutting, mix-shift of advertising dollars from linear TV to OTT/CTV and growing demand for online sports betting.
We need to keep track of this one.-HOTH--
Very early study but very exciting)
Very early study but very exciting)
- Hoth Therapeutics(NASDAQ:HOTH) perks up 8.7% premarket after recent findings from North Carolina State University suggest that the company's new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by "mutating" the mRNA before it can deliver instructions for manufacturing the gene responsible for cell proliferation.
- "We are altering the message that makes the protein – flipping an 'on' switch to 'off,'" says Glenn Cruse, assistant professor of immunology at North Carolina State University and a Scientific Advisor to Hoth. "If you get mRNA to produce a protein that is mutated and severely truncated, your cell will recognize that and degrade the message so that the protein isn't produced."
- The researchers used their frameshifted c-KIT mRNA approach on mast cell leukemia cells in vitro and found that KIT protein expression, signaling and function were reduced.
- The cancer cells stopped proliferating and began dying within hours.
- In a mouse model, tumor growth and infiltration of other organs were reduced, and tumor cell death increased when the frameshifted c-KIT mRNA was induced.
- "The other advantage to our technique is that it solves the problem of degradation evasion," Cruse says.
- The research appears in Molecular Therapy and is supported by the National Institutes of Health.
- Also, an article written by NC State says that, in a mouse model, frameshifting directed at the c-KIT gene reduced mast cell tumor size and prevented infiltration into other organs.
- Earlier this year in April, Hoth announced that its novel HT-KIT exhibited highly positive results in humanized mast cell neoplasm models for mast cell leukemia and mast cell sarcoma.
FULC- Nice Trade!
936 followersFulcrum Therapeutics, Inc.
23.15
4.38(+23.34%)<----------------
I have heard of them but not familiar...
This is rather interesting in that they dropped that secondary news with thegood news right off the bat- that's the way to do it! Because it can be seen now as good news-- providing fnding for a good purpose not just enriching the management who pay themselves in options...
You have a good one here! Morgan Stanly likes alot!
- Despite over twofold rise in value on Tuesday, the firm thinks that Fulcrum Therapeutics(NASDAQ:FULC)could at least double from current price levels as they upgraded the stock to overweight from equal weight.
- The price target upped to $34 from $12 implies a premium of ~81.1% to the last close.
- Coupang (NYSE:CPNG) is scheduled to announce Q2 earnings results on Wednesday, August 11th, after market close.
- The consensus EPS Estimate is -$0.14
- Honestly I could see them breaking even to even doing +.05 Cents A huge surprise. But I have not seen any analysts agreeing with me no EPS upgrades... I could be wrong but I think they have the ability to flip the EPS switch when they want (lowering costs) and now would be a fine time to show how much faster they have reached profitability than Amazon...
There's a rumor going around that the Amazon Prime trucks you may see I have not are Spy Trucks! That they are filed with radar, LIDAR and Wave length capture tech... that they are gathering some info on folks.... They are tapping into your AMZN doorbells and RING tech and the talking Alexia will download to the trucks as they drive by!!! Not carrying Boxes!!!!
Just a rumor...
ok, here is my XAIR prior post just cut and pasted with the addition of #3 the at home trial and #4 tumor.
Beyond Air Xair reported earnings and did a conference call today.
Transcript of call: https://seekingalpha.com/article/44...i-on-q1-2022-results-earnings-call-transcript
I tried pulling out some useful dates:
1) They anticipate hearing about the FDA approval for lungfit use on newborns end of September. They sound really confident about this.
If approved: "The first major conference following the expected timeline for FDA approval is the AARC or American Association for Respiratory Care in Phoenix in early November. And so, we are targeting that meeting as the first introduction of LungFit PH to the world."
2) Currently in pilot trial for lungfit use for acute viral pneumonia (including Covid) in adults. Have released some findings, plan to release further findings in upcoming, as yet unnamed, scientific meeting. Have data as well on a trial for young children with bronchiolitis (that trial is currentlysuspended due to covid).
The plan moving forward with these trials:
"Once this pilot trial is complete, our plan is to submit the entirety of the data at 150-160 parts per million NO in both hospitalized adult and infant viral pneumonia patient populations as one comprehensive data package to the FDA. We would like to move to a pivotal all-common [ph] trial for LungFit Pro in patients hospitalized with acute viral pneumonia and anticipate starting this study in the fourth quarter of calendar year 2022, the timing of which is due to the seasonality of most respiratory viruses."
3) dates for the self-treat at-home trial for LungFit Pro:
"...our ongoing non-tuberculous mycobacteria or NTM pilot study. We began screening patients for our LungFit Pro program in NTM in December 2020, and are on-track to report interim data at a conference in the fall of 2021 with top-line results coming later in the second quarter of calendar year 2022.
4) tumor study:
"We also expect to receive regulatory clearance to start human studies in our solid tumor program using ultra-high concentration gNO around the end of calendar year 2021 and begin enrolling patients in early 2022."
The tumor study is not currently a top priority of the company: "Though we are highly encouraged by the results from the solid tumor program, our LungFit platform remains the focus of Beyond Air."
What about BLUE Stoney?
Are they not working on the exact same thing with the same tech?
Its friggin way down too.
$19